Clinical trials: CAR-T Therapy Complications
Autoimmune Diseases, Systemic Lupus Erthematosus (SLE)
Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune Disease
This is an exploratory, open-label, single-arm Phase 1 clinical study designed to evaluate the safety, tolerability, and preliminary efficacy of QT-219C.
- Conditions
- Autoimmune Diseases, Systemic Lupus Erthematosus (SLE), Multi-Drug Resistant Nephrotic Syndrome, IgA Nephropathy (IgAN)
- Trial name
- NCT07507201
- Testing
- UCAR T-cell
- Where
- China
- Volunteers
- 15 people
- Sponsor
- The Children's Hospital of Zhejiang University School of Medicine
HPV-Associated Cervical Carcinoma, HPV-Related Carcinoma
E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers
The goal of this study is to determine the feasibility of administration of a single dose of E7 TCR-T cells as induction therapy prior to definitive treatment (chemoradiation or surgery) of locoregionally advanced HPV-associated…
- Conditions
- HPV-Associated Cervical Carcinoma, HPV-Related Carcinoma, HPV-Related Malignancy, HPV Positive Oropharyngeal Squamous Cell Carcinoma
- Trial name
- NCT05639972
- Testing
- E7 TCR-T cells, Aldesleukin
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Christian Hinrichs
Systemic Lupus Erythematosus, Lupus Nephritis
CHT105 for the Treatment of Refractory Lupus Nephritis
Systemic lupus erythematosus (SLE) is the most common systemic autoimmune disease in China. The kidneys are the organ most frequently affected in SLE and a major cause of mortality among SLE patients.
- Trial name
- NCT07517536
- Testing
- anti-CD19/70 CAR T cells (CHT105)
- Where
- China
- Volunteers
- 14 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Systemic Lupus Erythematosus
A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in Participants With Severe, Treatment-refractory Systemic Lupus Erythematosus (SLE)
The purpose of this study is to evaluate the safety and tolerability of P-CD19CD20-ALLO1 in participants with highly active, severe, refractory SLE with or without lupus nephritis (LN).
- Trial name
- NCT06984341
- Testing
- P-CD19CD20-ALLO1 Cells, Cyclophosphamide, Fludarabine
- Where
- 2 sites in United States
- Sponsor
- Genentech, Inc.
Multiple Myeloma, Allogeneic Stem Cell Transplantation
Trial of an Investigational Drug After Rejecting the Relapse of an Allogeneic Transplant
Most patients with multiple myeloma (MM) die due to relapse resistant to current treatment, including treatment with anti-B cell maturation antigen (BCMA) CAR-T cells.
- Trial name
- CARTemis-1 (NCT05982275)
- Testing
- CARTemis-1
- Where
- 5 sites in Spain
- Volunteers
- 25 people
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Pediatric Solid Tumor, Osteosarcoma
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
3CAR is being done to investigate an immunotherapy for patients with solid tumors. It is a Phase I clinical trial evaluating the use of autologous T cells genetically engineered to express B7-H3-CARs for patients ≤ 21 years old…
- Conditions
- Pediatric Solid Tumor, Osteosarcoma, Rhabdomyosarcoma, Neuroblastoma
- Trial name
- NCT04897321
- Testing
- Fludarabine, Cyclophosphamide, MESNA
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- St. Jude Children's Research Hospital
Kidney Transplant Rejection, End Stage Renal Disease
Long-Term Follow-Up of TX200-TR101 (STEADFAST Long Term)
This long-term follow-up study is being conducted to collect long-term (up to 15 years post-infusion) safety and tolerability data from subjects enrolled in studies evaluating TX200-TR101.
- Trial name
- NCT05987527
- Testing
- Blood sample
- Where
- 5 sites in Belgium, Netherlands and 1 more
- Volunteers
- 11 people
- Sponsor
- Sangamo Therapeutics
Lupus Nephritis, Lupus Nephritis - World Health Organization (WHO) Class III
KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis
A Study of Anti-CD19 Chimeric Antigen Receptor T Cell Therapy for Subjects With Refractory Lupus Nephritis
- Conditions
- Lupus Nephritis, Lupus Nephritis - World Health Organization (WHO) Class III, Lupus Nephritis - WHO Class IV
- Trial name
- NCT05938725
- Testing
- KYV-101 anti-CD19 CAR-T cell therapy, Standard lymphodepletion regimen
- Where
- 6 sites in United States
- Volunteers
- 6 people
- Sponsor
- Kyverna Therapeutics
Epithelial Ovarian Cancer
A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-M23, a CAR-T Cell Therapy Targeting MSLN in Patients With Relapsed and Refractory Epithelial Ovarian Cancer
This study is a prospective, single-arm, open-label, single-dose dose finding and extension study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor efficacy profiles of the LCAR-M23 CAR-T cell therapy in…
- Trial name
- NCT04562298
- Testing
- LCAR-M23 cells
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Shanghai East Hospital
Rhabdomyosarcoma, Ewing Sarcoma
Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)
This is a phase I dose-escalation study to determine the safety and feasibility of autologous CAR-TA T cells (B7-H3 CAR+ T cells administered with DNR-PRAME Tumor Antigen-specific T cells) following lymphodepleting chemotherapy…
- Conditions
- Rhabdomyosarcoma, Ewing Sarcoma, Neuroblastoma, Wilms Tumor
- Trial name
- SABRE (NCT07172958)
- Testing
- Selective Antigen Specific dTβRII-expressing T cells combined with B7-H3 CAR T cells
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Children's National Research Institute
Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN)
Equecabtagene Autoleucel Injection (Eque-cel) for Relapsed/Refractory Systemic Lupus Erythematosus (SLE)
This is a single-center, open-label, exploratory clinical study to evaluate the efficacy and safety of Equecabtagene Autoleucel Injection (Eque-cel) in patients with Relapsed /refractory systemic lupus erythematosus (SLE).
- Trial name
- NCT06902844
- Testing
- Equecabtagene Autoleucel Injection
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Tongji Hospital
Multi-Drug Resistant Nephrotic Syndrome, CAR-T Cell Therapy
Study of Therapeutic Efficacy of CAR-T Cell Therapy in Patients With MDR-SRNS
This is an investigator-initiated trial aimed at assessing the safety and efficacy of anti-BCMA/CD70 CAR-T cells in the treatment of patients with Multi-drug resistant SRNS
- Trial name
- NCT06553898
- Testing
- anti-BCMA/CD70 CAR-T cells
- Where
- China
- Volunteers
- 18 people
- Sponsor
- The Children's Hospital of Zhejiang University School of Medicine
SLE, Systemic Lupus Erythematosus (SLE)
CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus
This is a single-center, single-arm, open-label phase 1/2 study of CART19 in children and young adults with refractory Systemic lupus erythematosus (SLE), including both patients diagnosed with lupus nephritis (LN) and patients…
- Conditions
- SLE, Systemic Lupus Erythematosus (SLE), CAR T Cell, CART19
- Trial name
- NCT06839976
- Testing
- CART19
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Children's Hospital of Philadelphia
Metastatic Tumor, Advanced Solid Tumor
A Clinical Study of Anti-CD70 UCAR-T in Relapsed or Refractory Solid Tumors
This is a single-center, single-arm ，open-label ，dose escalation and dose extension study. In this study we plan to evaluate the safety and efficacy of CD70-targeting UCAR-T cells in the treatment of CD70-positive refractory or…
- Conditions
- Metastatic Tumor, Advanced Solid Tumor, Renal Cell Carcinoma, Ovarian Cancer
- Trial name
- NCT06383507
- Testing
- CHT101
- Volunteers
- 18 people
- Sponsor
- Zhejiang University
Autoimmune Diseases, Systemic Lupus Erthematosus (SLE)
CD19/BCMA UCAR-T for B Cell-Related Autoimmune Disease
This is an exploratory, open-label, single-arm clinical study designed to evaluate the safety, tolerability, and preliminary efficacy of QT-219CX.
- Conditions
- Autoimmune Diseases, Systemic Lupus Erthematosus (SLE), Multi-Drug Resistant Nephrotic Syndrome, IgA Nephropathy (IgAN)
- Trial name
- NCT07586267
- Testing
- QT-219CX
- Where
- China
- Volunteers
- 15 people
- Sponsor
- The Children's Hospital of Zhejiang University School of Medicine
Metastatic Tumor, Renal Cell Carcinoma
Clinical Study of CD70-targeted CAR-T Therapy for Advanced/Advanced Renal Cancer
This is a phase I clinical study to evaluate the safety and tolerability of CAR-T in patients with advanced/metastatic renal cell carcinoma, and to obtain the maximum tolerated dose of CAR-T and phase II Recommended dose.
- Conditions
- Metastatic Tumor, Renal Cell Carcinoma, Advanced Cancer
- Trial name
- NCT05420519
- Testing
- CD70 CAR-T cells
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Ovarian Cancer, Fallopian Tube Carcinoma
SCT-001 CAR T Cells Therapy for Relapsed and Refractory Ovarian Cancer
This study is an open-label, dose-escalation, investigator-initiated phase I interventional clinical study. To evaluate the safety, tolerability and preliminary efficacy of SCT-001 CAR-T cell injection in subjects with relapsed…
- Conditions
- Ovarian Cancer, Fallopian Tube Carcinoma, Peritoneal Carcinoma
- Trial name
- NCT06846424
- Testing
- SCT-001 CAR-T cells
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Shanghai Gynecologic Oncology Group
Lupus Nephritis
Universal CAR-T Cell Therapy for Refractory Lupus Nephritis
This investigator-initiated trial aims to assess the efficacy and safety of combination therapy using universal CAR-T cells targeting BCMA and CD19 in refractory lupus nephritis.
- Trial name
- NCT06681337
- Testing
- BCMA CART + CD19 CART
- Volunteers
- 10 people
- Sponsor
- Bioray Laboratories
Non-Small Cell Lung Cancer, Colorectal Cancer
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
This is a Phase 1 study of FT836 administered in participants with advanced solid tumors. The primary objectives of the study are to evaluate the safety and tolerability of FT836 with or without chemotherapy and/or trastuzumab or…
- Conditions
- Non-Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Ovarian Cancer
- Trial name
- NCT07216105
- Testing
- FT836, Cetuximab, Trastuzumab
- Where
- 5 sites in United States
- Volunteers
- 119 people
- Sponsor
- Fate Therapeutics
Colorectal Cancer, Ovarian Cancer
αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors
This is a single arm, open-label, dose escalation clinical study to evaluate the safety and tolerability of autologous mesothelin (MSLN)-targeted chimeric antigen receptor (MSLN-CAR) T cells secreting PD-1 nanobodies…
- Trial name
- NCT04503980
- Testing
- αPD1-MSLN-CAR T cells
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Shanghai Cell Therapy Group Co.,Ltd